孟鲁司特钠与氯雷他定在上呼吸道感染后咳嗽患者治疗中的应用
|
摘要
目的探讨孟鲁司特钠与氯雷他定在上呼吸道感染(上感)后咳嗽患者治疗中的应用效果。方法选取2015年10月至2017年5月期间在本院呼吸内科就诊的68例上感后咳嗽患者,所有患者均接受常规基础治疗,对照组仅给予孟鲁司特钠于睡前口服,观察组加用氯雷他定,对比两组治疗前后咳嗽症状评分及治疗效果,评价药物安全性,同时观察复发情况。结果治疗后,观察组咳嗽症状评分为(0.07±0.01)分,明显低于对照组的(1.12±0.09)分,观察组咳嗽症状改善情况优于对照组(P<0.05),观察组治疗总有效率为97.06%,明显高于对照组的85.29%,观察组整体疗效明显优于对照组(P<0.05),观察组药物不良反应发生率为2.94%,明显低于对照组的14.71%(P<0.05)。观察组治疗结束后随访过程中有1例复发(3.03%),对照组有4例复发(13.79%),观察组复发率明显低于对照组(c2=11.740,P<0.05)。结论采用孟鲁司特钠与氯雷他定联合治疗上感后咳嗽能够明显改善患者咳嗽症状,提升疗效,减少复发,值得临床推广。
Objective To investigate the effect of montelukast sodium and loratadine in the treatment of cough after upper respiratory tract infection(upper sensation). Methods 68 patients with post-infectious cough were selected from October 2015 to May 2017. All patients received routine basic treatment. The control group was given montelukast sodium orally before bedtime. The observation group was given loratadine. The cough symptom scores and therapeutic effects before and after treatment were compared between the two groups. The drug safety was evaluated and the recurrence was observed. Results After treatment, the cough symptom score of the observation group was(0.07±0.01), which was significantly lower than that of the control group(1.12±0.09). The improvement of cough symptoms in the observation group was better than that of the control group(P<0.05). The total effective rate of the observation group was 97.06%, which was significantly higher than that of the control group(85.29%). The overall curative effect of the observation group was significantly better than that of the control group(P<0.05). The adverse drug reactions in the observation The rate was 2.94%, which was significantly lower than 14.71% in the control group(P<0.05). During the follow-up period after the end of treatment, there was 1 case of recurrence(3.03%) in the observation group and 4 cases of recurrence(13.79%) in the control group. The recurrence rate in the observation group was significantly lower than that in the control group(c2=11.740, P<0.05). Conclusion The combination of montelukast sodium and loratadine can significantly improve the symptoms of cough, improve the curative effect and reduce the recurrence, which is worthy of clinical promotion.
Objective To investigate the effect of montelukast sodium and loratadine in the treatment of cough after upper respiratory tract infection(upper sensation). Methods 68 patients with post-infectious cough were selected from October 2015 to May 2017. All patients received routine basic treatment. The control group was given montelukast sodium orally before bedtime. The observation group was given loratadine. The cough symptom scores and therapeutic effects before and after treatment were compared between the two groups. The drug safety was evaluated and the recurrence was observed. Results After treatment, the cough symptom score of the observation group was(0.07±0.01), which was significantly lower than that of the control group(1.12±0.09). The improvement of cough symptoms in the observation group was better than that of the control group(P<0.05). The total effective rate of the observation group was 97.06%, which was significantly higher than that of the control group(85.29%). The overall curative effect of the observation group was significantly better than that of the control group(P<0.05). The adverse drug reactions in the observation The rate was 2.94%, which was significantly lower than 14.71% in the control group(P<0.05). During the follow-up period after the end of treatment, there was 1 case of recurrence(3.03%) in the observation group and 4 cases of recurrence(13.79%) in the control group. The recurrence rate in the observation group was significantly lower than that in the control group(c2=11.740, P<0.05). Conclusion The combination of montelukast sodium and loratadine can significantly improve the symptoms of cough, improve the curative effect and reduce the recurrence, which is worthy of clinical promotion.
引文
[1]周凌,蒋丕萍,张爱红.孟鲁司特钠治疗老年患者感染后咳嗽的疗效观察[J].中国老年保健医学,2016,14(1):55-56.
[2]孙成山.孟鲁司特钠与氯雷他定在上呼吸道感染后咳嗽患者治疗中的临床效果[J].世界最新医学信息文摘,2016,16(52):142-148.
[3]王连庆,魏丽娟.孟鲁司特钠联合氯雷他定治疗上呼吸道感染后咳嗽疗效观察[J].临床医药实践,2010,19(17):661-662.
[4]赵启凤.酮替芬联合孟鲁司特钠治疗上呼吸道感染后咳嗽的疗效观察[J].中国医药指南,2014,12(1):112-113.
[5]杨海娟,梁中信,曹素芬,等.孟鲁司特钠用于上呼吸道感染后出现咳嗽症状患儿的临床疗效分析[J].中外医疗,2015,34(1):103-104.
[6]乐德进,耿慧.孟鲁司特钠联合氯雷他定治疗上呼吸道感染后咳嗽的疗效观察[J].中国处方药,2016,14(12):51-52.
[7]黄丽华.孟鲁司特钠片治疗儿童急性上呼吸道感染后咳嗽的疗效[J].求医问药,2012,10(11):1001.
[8]冯德华,樊长征,苗青,等.健脾补肺法治疗感染后气道高反应咳嗽60例临床观察[J].中医杂志,2013,54(12):1025-1027.
[2]孙成山.孟鲁司特钠与氯雷他定在上呼吸道感染后咳嗽患者治疗中的临床效果[J].世界最新医学信息文摘,2016,16(52):142-148.
[3]王连庆,魏丽娟.孟鲁司特钠联合氯雷他定治疗上呼吸道感染后咳嗽疗效观察[J].临床医药实践,2010,19(17):661-662.
[4]赵启凤.酮替芬联合孟鲁司特钠治疗上呼吸道感染后咳嗽的疗效观察[J].中国医药指南,2014,12(1):112-113.
[5]杨海娟,梁中信,曹素芬,等.孟鲁司特钠用于上呼吸道感染后出现咳嗽症状患儿的临床疗效分析[J].中外医疗,2015,34(1):103-104.
[6]乐德进,耿慧.孟鲁司特钠联合氯雷他定治疗上呼吸道感染后咳嗽的疗效观察[J].中国处方药,2016,14(12):51-52.
[7]黄丽华.孟鲁司特钠片治疗儿童急性上呼吸道感染后咳嗽的疗效[J].求医问药,2012,10(11):1001.
[8]冯德华,樊长征,苗青,等.健脾补肺法治疗感染后气道高反应咳嗽60例临床观察[J].中医杂志,2013,54(12):1025-1027.